Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary

Enliven Therapeutics, Inc.

Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.
Joint investor conference call held on October 13, 2022 to discuss the transaction and its rationale.
No deal value, premium, or expected close date disclosed in this filing or the appended transcript excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.